Inclusion Criteria:  18y ≤ age ≤ 80y; De-novo coronary artery lesions with indication for PCI; Target lesion diameter stenosis ≥ 70% (visual) or ≥ 50% (visual) with evidence of ischemia; Target lesion reference vessel diameter (2.5mm-4.0 mm), Length of a single target lesion ≤ 35mm; Total treated lesion length ≤ 60 mm; Vessels treated ≤ 2; only one DCB/DES is allowed for each target vessel; ≤ 2 non-target lesions (non-TL) are allowed, and can not be in the same vessel as the target lesion (randomization should be implemented only after the successful treatment of all non-TL); Patients who are able to complete the follow-up and compliant to the prescribed medication.  Exclusion Criteria:  Myocardial infarction (< 7 days); Heavy thrombotic burden in target vessel; eGFR < 30ml/min or hemodialysis patients; Other cardiovascular and cerebrovascular percedures planned within 12 months after index PCI; Patients with contraindications to antiplatelet agents and anticoagulants; or bleeding tendency, history of active peptic ulcer, and stroke within 6 months; Life expectancy of less than 1 years; Patient is a woman who is pregnant or nursing; Known allergic to medications such as Aspirin, Heparin, antiplatelet drugs, paclitaxel, or contrast; patients with systemic lupus erythematosus or other systemic immune diseases; Chronic total occlusion lesion; Unprotected left main disease; Bifurcation lesion requiring 2 stents; Ostial lesions, distance from left main ≤ 2mm; Severe calcification or distortion; Arterial, venous or prosthetic grafts; In-stent stenosis requiring revascularization (defined as stenosis≥50% by visual or positive functional assessments in any vessel); Myocardial bridging located at target lesions; Currently participating in another trial and not yet at its primary endpoint; Participants deemed unsutable to be enrolled by investigators for unable to comply to protocol or other reasons.